How would you explain supraventricular tachycardia (SVT) to a patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Explaining Supraventricular Tachycardia (SVT)

Medical Explanation

Supraventricular tachycardia is a rapid heart rhythm (>100 beats per minute) originating from electrical circuits in or above the heart's AV node, most commonly caused by reentry mechanisms where electrical impulses travel in abnormal circular pathways. 1

Mechanism and Types

  • SVT results from reentry circuits where an electrical impulse conducts around a fixed obstacle or through dual pathways with different conduction speeds and refractory periods 1
  • The most common types are:
    • AVNRT (AV nodal reentrant tachycardia): Uses two pathways within the AV node itself 1
    • AVRT (AV reentrant tachycardia): Involves an accessory pathway bypassing the AV node 1
    • Atrial tachycardia: Originates from abnormal electrical activity in the atria 2

Clinical Presentation

The hallmark symptom is sudden-onset, rapid, regular palpitations that start and stop abruptly (paroxysmal), distinguishing it from sinus tachycardia which accelerates and decelerates gradually 1

Common symptoms include:

  • Palpitations (most frequent) 1
  • "Neck pounding" or "shirt flapping" sensations, particularly in AVNRT due to atrial contraction against closed AV valves (cannon a-waves) 2
  • Lightheadedness (common) and syncope (occurs in ~15% of patients, usually at onset or termination) 1
  • Chest discomfort, dyspnea, fatigue, anxiety 1
  • Polyuria from atrial natriuretic peptide release 1

Important Clinical Context

  • SVT most often occurs in structurally normal hearts, particularly in younger individuals 1
  • Episodes can terminate with vagal maneuvers (Valsalva, carotid massage), which strongly suggests reentrant tachycardia involving AV nodal tissue 1
  • Prolonged SVT (weeks to months) with fast ventricular rates can cause tachycardia-mediated cardiomyopathy 1
  • Syncope warrants serious evaluation, especially in patients with pre-excitation patterns, as it may indicate risk for dangerous arrhythmias 1

Patient-Friendly Explanation

Your heart has an electrical problem where signals travel in a circular loop instead of following the normal path, causing your heart to suddenly race very fast (usually 150-250 beats per minute). 1, 3

What You'll Experience

  • Your heart will suddenly start racing without warning and feel like it's pounding very fast and regularly, like a drum beating rapidly 1
  • You might feel pounding in your neck or a fluttering sensation in your chest, almost like your shirt is flapping 2
  • You may feel dizzy, lightheaded, short of breath, or anxious when episodes occur 1
  • The racing usually stops just as suddenly as it started, sometimes after you bear down (like having a bowel movement) or cough 1
  • You might need to urinate more than usual after an episode 1

What Makes This Different from Normal

  • Normal anxiety or stress causes your heart to speed up gradually and slow down gradually 1
  • SVT starts instantly—like flipping a light switch—and your heart races at the same fast speed the entire time 1
  • It can happen at rest, not just during exercise or stress 2

What You Should Know

  • This is usually not life-threatening, though it feels frightening 4, 5
  • Most people with SVT have normal, healthy hearts—this is an electrical wiring problem, not a structural heart problem 1
  • If you feel faint or pass out during episodes, tell your doctor immediately as this needs urgent evaluation 1
  • Episodes may become more frequent over time if untreated 5
  • Driving during episodes can be dangerous—57% of patients experience SVT while driving, with 14% experiencing syncope 2

What Happens Next

  • We need to capture your heart rhythm on an ECG during an episode to confirm the diagnosis and determine the exact type 1
  • You may need to wear a heart monitor (Holter or event recorder) to catch an episode since they come and go 1, 6
  • Treatment is highly effective: catheter ablation (a procedure to fix the electrical pathway) has a 95% success rate with less than 5% recurrence 6, 7
  • If episodes are infrequent and mild, you may not need treatment, but most patients prefer definitive treatment because episodes tend to worsen over time 5

Related Questions

How should supraventricular tachycardia (SVT) be treated acutely and for long‑term management?
What is the appropriate management for a patient with frequent episodes of supraventricular tachycardia (SVT)?
What is the initial management and treatment for supraventricular tachycardia (SVT) in hemodynamically stable patients?
What are the criteria for Supraventricular Tachycardia (SVT)?
What are the recommended drug dosages for acute and chronic management of supraventricular tachycardia (SVT) in adults?
For an incarcerated hernia, should a CT scan be performed with oral (by mouth) contrast, intravenous contrast, or both?
What is drug‑induced immune thrombocytopenia (ITP)?
What are the possible causes of chest pain when cardiac biomarkers are negative?
What is the likely diagnosis and recommended management for a patient with ferritin 332 µg/L, serum iron 179 µg/dL, transferrin saturation 51 %, total iron‑binding capacity 351 µg/dL, bilirubin 1.6 mg/dL, alanine aminotransferase 44 U/L, aspartate aminotransferase 29 U/L, and alkaline phosphatase 46 U/L?
In a patient with type 2 diabetes mellitus taking prednisone 156 mg (tapering to 80 mg) and currently on neutral protamine Hagedorn (NPH) insulin 32 units with an insulin‑to‑carbohydrate ratio of 1 unit per 5 g carbohydrate and a correction factor of 1 unit per 15 mg/dL, and blood glucose readings of 83 mg/dL at 11 am, 178 mg/dL at 5 pm, and 249 mg/dL at 9 pm, what should the NPH dose, insulin‑to‑carbohydrate ratio, and correction factor be adjusted to?
Should a patient with myasthenia gravis classified as Osserman class III be intubated?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.